4 Citations (Scopus)

Abstract

The number of allogeneic and autologous bone marrow transplants continues to grow worldwide. Bone marrow transplantation (BMT) has become standard therapy for many patients with leukemia, lymphoma, multiple myeloma and testicular cancer. Encouraging results of autologous BMT in treating patients with poor-risk breast cancer have led to this approach being tested in nationwide randomized trials. In order to increase availability and efficacy of BMT, other sources of hematopoietic cells are explored for transplantation, such as from HLA-matched unrelated volunteer donors, partially matched related donors, placental/umbilical cord blood and allogeneic peripheral blood. Relapse of original malignancy remains the main obstacle for the success of BMT. Recent clinical investigations have demonstrated that donor-derived peripheral blood leukocytes are effective in inducing remissions in patients with hematological malignancies who relapse after allogeneic BMT. BMT procedures are associated with significant complexity and should be carried out only in transplant units that meet adequate standards. In order to better define the role of BMT in treating cancer, more phase III clinical trials are needed. The future of BMT will depend on further improvements in its efficacy and economic constraints.

Original languageEnglish (US)
Pages (from-to)159-168
Number of pages10
JournalOncologist
Volume1
Issue number3
StatePublished - Dec 1 1996

Fingerprint

Bone Marrow Transplantation
Neoplasms
Tissue Donors
Transplants
Recurrence
Unrelated Donors
Phase III Clinical Trials
Autologous Transplantation
Cell Transplantation
Homologous Transplantation
Testicular Neoplasms
Hematologic Neoplasms
Multiple Myeloma
Fetal Blood
Volunteers
Lymphoma
Leukemia
Leukocytes
Bone Marrow
Economics

Keywords

  • Allogeneic
  • Autologous
  • Bone marrow transplantation
  • Review
  • Standards
  • Stem cell
  • Utilization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bone marrow transplantation for cancer - An update. / Pavletic, Z. Steven; Armitage, James Olen.

In: Oncologist, Vol. 1, No. 3, 01.12.1996, p. 159-168.

Research output: Contribution to journalArticle

Pavletic, ZS & Armitage, JO 1996, 'Bone marrow transplantation for cancer - An update', Oncologist, vol. 1, no. 3, pp. 159-168.
Pavletic, Z. Steven ; Armitage, James Olen. / Bone marrow transplantation for cancer - An update. In: Oncologist. 1996 ; Vol. 1, No. 3. pp. 159-168.
@article{0815c4a449e34d5190f61b3ba5016bfb,
title = "Bone marrow transplantation for cancer - An update",
abstract = "The number of allogeneic and autologous bone marrow transplants continues to grow worldwide. Bone marrow transplantation (BMT) has become standard therapy for many patients with leukemia, lymphoma, multiple myeloma and testicular cancer. Encouraging results of autologous BMT in treating patients with poor-risk breast cancer have led to this approach being tested in nationwide randomized trials. In order to increase availability and efficacy of BMT, other sources of hematopoietic cells are explored for transplantation, such as from HLA-matched unrelated volunteer donors, partially matched related donors, placental/umbilical cord blood and allogeneic peripheral blood. Relapse of original malignancy remains the main obstacle for the success of BMT. Recent clinical investigations have demonstrated that donor-derived peripheral blood leukocytes are effective in inducing remissions in patients with hematological malignancies who relapse after allogeneic BMT. BMT procedures are associated with significant complexity and should be carried out only in transplant units that meet adequate standards. In order to better define the role of BMT in treating cancer, more phase III clinical trials are needed. The future of BMT will depend on further improvements in its efficacy and economic constraints.",
keywords = "Allogeneic, Autologous, Bone marrow transplantation, Review, Standards, Stem cell, Utilization",
author = "Pavletic, {Z. Steven} and Armitage, {James Olen}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "1",
pages = "159--168",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Bone marrow transplantation for cancer - An update

AU - Pavletic, Z. Steven

AU - Armitage, James Olen

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The number of allogeneic and autologous bone marrow transplants continues to grow worldwide. Bone marrow transplantation (BMT) has become standard therapy for many patients with leukemia, lymphoma, multiple myeloma and testicular cancer. Encouraging results of autologous BMT in treating patients with poor-risk breast cancer have led to this approach being tested in nationwide randomized trials. In order to increase availability and efficacy of BMT, other sources of hematopoietic cells are explored for transplantation, such as from HLA-matched unrelated volunteer donors, partially matched related donors, placental/umbilical cord blood and allogeneic peripheral blood. Relapse of original malignancy remains the main obstacle for the success of BMT. Recent clinical investigations have demonstrated that donor-derived peripheral blood leukocytes are effective in inducing remissions in patients with hematological malignancies who relapse after allogeneic BMT. BMT procedures are associated with significant complexity and should be carried out only in transplant units that meet adequate standards. In order to better define the role of BMT in treating cancer, more phase III clinical trials are needed. The future of BMT will depend on further improvements in its efficacy and economic constraints.

AB - The number of allogeneic and autologous bone marrow transplants continues to grow worldwide. Bone marrow transplantation (BMT) has become standard therapy for many patients with leukemia, lymphoma, multiple myeloma and testicular cancer. Encouraging results of autologous BMT in treating patients with poor-risk breast cancer have led to this approach being tested in nationwide randomized trials. In order to increase availability and efficacy of BMT, other sources of hematopoietic cells are explored for transplantation, such as from HLA-matched unrelated volunteer donors, partially matched related donors, placental/umbilical cord blood and allogeneic peripheral blood. Relapse of original malignancy remains the main obstacle for the success of BMT. Recent clinical investigations have demonstrated that donor-derived peripheral blood leukocytes are effective in inducing remissions in patients with hematological malignancies who relapse after allogeneic BMT. BMT procedures are associated with significant complexity and should be carried out only in transplant units that meet adequate standards. In order to better define the role of BMT in treating cancer, more phase III clinical trials are needed. The future of BMT will depend on further improvements in its efficacy and economic constraints.

KW - Allogeneic

KW - Autologous

KW - Bone marrow transplantation

KW - Review

KW - Standards

KW - Stem cell

KW - Utilization

UR - http://www.scopus.com/inward/record.url?scp=0008886361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008886361&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0008886361

VL - 1

SP - 159

EP - 168

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -